NEW ZEALAND – DSM-Firmenich, a leading innovator in health, nutrition, and beauty, has received approval for four human milk oligosaccharide (HMO) ingredients for use in infant formula products in Australia and New Zealand.

The approval, granted by the Food Standards Australia New Zealand (FSANZ) following an application by Glycom A/S, marked a significant milestone in advancing early-life nutrition solutions more closely aligned with breastmilk composition.

The approved HMO ingredients include GlyCare 2’-fucosyllactose/difucosyllactose (2’-FL/DFL), GlyCare lacto-N-tetraose (LNT), GlyCare 6’-sialyllactose (6’-SL) sodium salt, and GlyCare™ 3’-sialyllactose (3’-SL) sodium salt.

DSM-Firmenich is the first HMO manufacturer to secure approval for these ingredients in the Australian and New Zealand regions.

According to the innovator, the approval not only validates the use of additional science-backed ingredients but also opens doors for innovative early-life nutrition solutions tailored to mimic breastmilk more closely.

The FSANZ assessment found no public health and safety concerns associated with incorporating these HMOs in infant formula products at specified levels.

An exclusive use period of 15 months has been granted for all four GlyCare HMO products.

The evaluation by FSANZ also acknowledged the potential health benefits of the HMOs for infants, including positive effects on gut microbiota, anti-pathogenic effects, suppression of inflammation, and support for immune responses and antigenic memory.

Christoph Röhrig, Head of HMO Regulatory at DSM-Firmenich, emphasized the company’s commitment to delivering safe and innovative infant nutrition solutions.

DSM-Firmenich was the first to introduce 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT) HMOs to Australia and New Zealand.

The approval of these additional ingredients marks a significant step towards advancing early life nutrition globally.

Maryse Darch, Regulatory & Scientific Affairs Manager at DSM-Firmenich, highlighted the importance of FSANZ opinions in supporting market access to HMOs in other regions, particularly in the Asia-Pacific area.

The company has also received approval for the same six HMO products in other markets, including the EU, US, Singapore, and Thailand, providing new commercialization opportunities globally for infant formula products with HMO blends that closely resemble those found in breastmilk.

Subscribe to our food and agriculture industry email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE